Partners
Partners

Partner 5 - Institut Gustave Roussy


Dr. Francoise Farace

 

Principal Investigator

 

Phone: +33 1 42 11 51 98

undefinedE-Mail

 

 

Institut Gustave Roussy

 

Edouard Vaillant, 114

94805 Villejuif

France

undefinedWebsite

CANCER-ID Team Gustave Roussy

Dr. Colin Lindsay

 

Postdoc

 

Phone: +33 1 42 11 51 97

undefinedE-Mail

 

 

Emma Pailler

 

PhD Student

 

Phone: +33 1 42 11 31 56

undefinedE-Mail

 

 

Marianne Oulhen

 

Engineer

 

Phone: +33 1 42 11 31 56

undefinedE-Mail

Fanny Billiot

 

Technician

 

Phone: +33 1 42 11 51 97

undefinedE-Mail

Institute presentation

The Gustave Roussy cancer center is one of the ten world leaders in the fight against cancer. Located south of Paris on a single site GR employs 2,000 professionals working in care, research, and teaching. As an expert center in dealing with complex cancers, Gustave Roussy brings together cutting-edge medical care and human support. Gustave Roussy’s specificity is based on its therapeutic innovation, which today puts it at the forefront in very promising areas such as personalised medicine and tomorrow’s therapies (immunotherapy, DNA repair inhibitors, epigenetic modulators). A key actor on the European and international oncology scene, Gustave Roussy applies a global approach to cancer, employing multidisciplinary teams to care for each patient and define by a multidisciplinary process the best treatments for them. Top level research, conducted at the very heart of the Institute, is aimed at the integration of basic, translational and clinical approaches, so that the results can be applied as quickly as possible for the benefit of the patient.
The CTC team (translational Research Laboratory / INSERM U981) has acquired a specific scientific expertise in the field of rare circulating cell populations including CTCs, circulating endothelial cells (CECs), circulating endothelial progenitor cells (CEPs). Research activities encompass the biological and clinical significance of these cell populations in solid tumors. Since 2005, the Circulating Cell Unit has conducted numerous studies (including multicentric studies) for the clinical evaluation of CECs, CEPs and CTCs. For CTCs, different technologies (CellSearch, ISET, microfluidic device) have been evaluated and implemented with original techniques for cytomorphological, phenotypical and molecular characterization.

CANCER-ID Consortium

CANCER-ID consortium

CANCER-ID Workpackages

CANCER-ID Work Plan

EUROPA - NEWS

News from the European Comission

What's new in Health and Life Sciences? Click here for news from the European Commission.

Search
Top
Home
Menu

EU logo
imi Logo
efpia Logo

News Section

Hands-on courses provided by our member TATAA Read more

Social Media

LinkedIn Cancer-ID